Morgan Stanley (MS)

Morgan Stanley (MS) closed at $148.02 in the latest trading session, marking a +2.76% move from the prior day.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Morgan Stanley (MS) have what it takes?

NEW YORK--(BUSINESS WIRE)--Morgan Stanley Investment Management (MSIM) announced today that the 1GT climate private equity strategy (1GT) participated in the $105 million Series C equity financing of Overhaul Group (Overhaul or the Company), a global leader of in-transit cargo risk management solutions. The Series C funding round was led by Springcoast Partners with participation from existing investor Edison Partners. This growth investment will support Overhaul's continued technological advan.

Gemini Space Station, the cryptocurrency company founded by twins Cameron and Tyler Winklevoss, has filed for an initial public offering in the United States. The company plans to list its shares on the Nasdaq Global Select Market under the ticker symbol “GEMI.

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth quality scores, and positive momentum, suitable for investors in the accumulation phase.

NEW YORK--(BUSINESS WIRE)--Morgan Stanley today declared a regular dividend on the outstanding shares of each of the following preferred stock issues: Floating Rate Non-Cumulative Preferred Stock, Series A - $337.28 per share (equivalent to $0.337280 per Depositary Share) 10 Percent Non-Cumulative Non-Voting Perpetual Preferred Stock, Series C - $25.00 per share Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series E - $455.21 per share (equivalent to $0.455208 per Depositary Share) Fix.

Morgan Stanley (MS) reported earnings 30 days ago. What's next for the stock?

NEW YORK--(BUSINESS WIRE)--Dan Simkowitz, Co-President of Morgan Stanley, will speak at the Barclays Global Financial Services Conference on September 10, 2025, at 9:00 a.m. (ET). Both live and on-demand versions of the webcast will be available on www.morganstanley.com in the Investor Relations section. Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With office.

MS hits a record $148.23 amid a market rally fueled by rate cut hopes, but rising costs and trading reliance pose challenges.

Zacks.com users have recently been watching Morgan Stanley (MS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Can JPMorgan's IB dominance, trading strength and diversified revenues give it an edge over Morgan Stanley in a volatile market? Let's take a closer look.

Danish renewable energy firm Ørsted announced a fully underwritten rights issue to raise the equivalent of $9.4 billion (60 billion Danish Kroner, DKK). The Danish state, which owns 50.1% of Ørsted, will subscribe for its pro rata share.

Morgan Stanley Q2 EPS Falls 38%

Morgan Stanley upgraded Afya to Equal Weight from Underweight with a price target of $17.50, down from $19, as part of a broader research note on Brazil Education Services. The new sector regulation will both reshape industry structure and reset economic equilibrium, the analyst tells investors in a research note. Despite long-term medical school risks, the firm sees strong short-term earnings and a narrower valuation gap relative to peers, Morgan Stanley added. 13 Aug

Morgan Stanley upgraded Y-mAbs Therapeutics to Equal Weight from Underweight with a price target of $8.60, up from $7, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.

Morgan Stanley analyst Elizabeth Porter downgraded Semrush to Equal Weight from Overweight with a price target of $9, down from $13. Momentum in enterprise and early AI solutions are not enough to offset increasing pressure at low-end customers, the analyst tells investors. While valuation is "undemanding," the lack of a product cycle catalyst gives the firm "limited conviction in upside catalysts to displace bear narratives," the analyst tells investors. 05 Aug